PTO/SB/17(11-00)

For use through 10/31//2002. OMB 0651-0032

Office: U.S. DEPARTMENT OF COMMERCE

n unles it displays a valid OMB control number U.S. Patent and Trac

Onder the rapel work reduction Act of 1999.						Complete if Known							
FERTRANSMITTAL						Application Number				09/863,976			
FEE TRANSMITTAL FOR FY 2001						Filing Date				May 23, 2001			
OET 0 3 MIN E						First Named Inventor				Farzan Rastinejad, et al.			
[\Z .S)													
TRANSIT rees are subject to annual Revision						Examiner Name				J. D. Goldberg			
Total Amount of Payment (\$)90.00						Group/Art Unit							
METHOD OF PAYMENT						Attorney Docket No. PC10228B FEE CALCULATION (continue)							
1. 🛛				 	3. ADDITIONAL FEES				COLATION		0	m	
			er is hereby authorized d credit any over payn		3. ADDITIONAL FEES					S	EC	Ö	
Deposit													
Account Number					Fee Code	Large Entity	Fee Code	Small Entity	Fee Description	" \$\frac{1}{12}	5	Fee Paid	
			•			Fee	*	Fee	=======================================		2002	m	
Deposit Pfizer Inc						(\$) 130	205	(\$) 65	Surcharge - lat	te fee or oath	2		
Account Name	Pilzeri	inc							ourona go la	<u>87</u>			
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17						50	227	25	Fee Description Surcharge – late fee or oath Surcharge–late filing fee or cover sheet				
Applicant claims small entity status.						130	139	130	Non-English sp	Non-English specification			
	37 CFR 1		i cinny status.		147	2,520	147	2,520	For filing a regu	uest for ex parte rexami	nation		
2. Payment Enclosed:						920*	112	920*		blication of SIR prior to			
Check	Cradio	Credit card Money Order Othe			113	1,840*	113	1,840*	Examiner action				
Check	C. Credit	caru	Money Order	Other	""	7,0.0	,,,	1,010	Examiner actio	blication of SIR after n			
FEE CALCULATION						110	215	55	Extension for reply within first month				
1. BASIC FILING FEE						400	216	200	Extension for re	xtension for reply within second month			
Large Entity	Small E	•			117	920	217	460	Extension for re	eply within third month			
Fee 1 Fee Code (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid	118	1,440	218	720	Extension for re	eply within fourth month	١ .		
105 740	201	355	Utility filing fee		128	1,960	228	980	Extension for reply within fifth month				
106 . 330	206	165	Design filing fee		119	320	219	160	Notice of Appeal				
107 510	207	255	Plant filing fee		120	320	220	160	Filing a brief in support of an appeal				
108 740	208	370	Reissue filing fee		121	280	221	140	Request for oral hearing				
114 160 214 80 filing fee SUBTOTAL (1) (5) 0.00					138 140	1,510 110	138 240	1,510	Petition to institute a public use proceeding				
2 EVEDA CI		IBTOTA	AL (1) L(S)	0.00	141	1,280	240	55 640	Petition to revive - unavoidable Petition to revive - unintentional				
2. EXTRA CI	AIMF	EES	Fee fro	m	142	1,280	242	640	Utility issue fee (or reissue)				
	30		ktra Claims belov '-5- v 18.		143	460	243	230	-				
Total Claims	30	-25**=	* -5- X 18.	00 = 90.00	143	460	243	230	Design issue fe	90			
Independent 1 3**= -0- χ 0.00 = 0.00 Claims				144 122	620	244	310	Plant issue fee	Plant issue fee				
Multiple Dependent 0.00 = 0.00						130	122	130	Petitions to the	titions to the Commissioner			
Large Entity Small Entity Fee Fee Fee Fee Description				123 126	50 180	123 126	50 180	Processing fee under 37 CFR 1.17(q)					
Code Code	code d	ode	i ee Description						Submission of Information Disclosure Stmt				
103 18	203	9	Claims in excess of		581	40	581	40	Recording each patent assignment per property (times number of properties)				
102 84	84 202 42 Independent claims in excess of 3		in excess of 3	146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))					
104 280	204	140	Multiple dependent	claim, if not paid				370	For each additional invention to be examined (37 CFR § 1.129(b))				
109 80	209 42 **Reissue independe			ent claims ginal patent	179 710		279	355	Request for Continued Examination(RCE)		CE)	į	
110 18 210 9 **Reissue claims in excess of 20 and over original patent						169 900 169 900 Request for expedited examination of a design application				а			
	SUBTO	ΓAL (2)	(\$)	90.00	Other (specify)								
** or number previ	ously paid,	, if great	er; For Reissues, see ab	ove	*Reduced by Basic Filing Fee Paid				Subtotal (3) 0.00				
SUBMITTED BY Complete (if applicable)													
Type or Printed N	lame	Victor	rictor Donahue Registration No.			35,492			Telephone 212-733-2739				
Signature		_	2.451					Date i//27/02 November 27, 2002					

Response to Requirement of Restriction September 27, 2002

Attorney Docket No. PC10228B

Ser. No. 09/863,976

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, addressed to the Commissioner for Patents, Washington, D.C. 20231, on this 27th day of November, 2002. (Signature of person mailing

Vilma Pizarro (Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Farzan Rastinejad, et al.

APPLICATION NO.: 09/863,976 Examiner: J. D. Goldberg

FILING DATE: May 23, 2001 Group Art Unit: 1614

TITLE: METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL

STABILITY OF A PROTEIN OF THE P53

FAMILY

Commissioner for Patents Washington, D.C. 20231

Sir:

Reply to Requirement of Restriction

The present Reply is in response to the Requirement of Restriction and Election mailed by the Examiner herein on September 27, 2002. A Petition for Extension of Time of one month (in duplicate) is enclosed.

The claims pending in the present application correspond identically to the claims originally filed in the parent application, serial number 09/443,542, which is being presently prosecuted and examined by Examiner Jerome D. Goldberg.

Applicants have carefully reviewed the restriction requirement. Prior to examination on the merits, and as is permitted, Applicants present herewith a new set of claims confined generally to a single independent invention for which examination is now requested.

The new claims, nos. 26-56 are directed to the method of screening for new drugs based on their interaction with and stabilization of p53 and related proteins. These claims are fully supported in the specification.

AMENDMENT

Please cancel Claims 1-25 without prejudice. Applicants reserve the right to again present these claims, or the subject matter thereof, in a following continuation application.